Gelonghui, May 14, 丨 Hehuang Pharmaceutical (00013.HK) announced the launch of a Chinese phase II/III clinical trial today to evaluate Hehuang Pharmaceutical's drug candidate surufatinib (surufatinib), the PD-1 antibody camrelizumab (camrelizumab) of Jiangsu Hengrui Pharmaceutical Co., Ltd. (“Hengrui Pharmaceutical”), albumin-conjugated paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of metastatic pancreatic conduction Ductal adenocarcinoma (PDAC) patients. Pancreatic duct adenocarcinoma is an exocrine tumor and the most common form of pancreatic cancer. The first subject was treated with the first dose on May 8, 2024.

Dr. Su Weiguo, CEO and Chief Scientific Officer of Hewong Pharmaceuticals, said, “New data, including clinical trials initiated by researchers published at the ASCO Gastrointestinal Cancer Symposium, shows that compared with existing chemotherapy-based metastatic pancreatic duct adenocarcinoma treatments, combination therapy with surufatinib, carrilizumab, and chemotherapy have good curative effects. We hope this collaboration will bring patients innovative treatment options that promise to change lives. ”